Skip to main content
GutCited

Lactobacillus rhamnosus GG için Antibiotic-Associated Diarrhea (AAD)

A

Meta-analyses demonstrate LGG reduces AAD incidence by 42-49%. Most effective when started within 48 hours of antibiotic initiation and continued 7 days after completion.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u002Dgg\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Sonuç

Meta-analyses demonstrate LGG reduces AAD incidence by 42-49%. Most effective when started within 48 hours of antibiotic initiation and continued 7 days after completion.

Key Study Findings

Observational Study n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None vs: None Outcome: Probiotic prescribing habits of Italian PCPs Etki: L. rhamnosus GG used by 91.8% None

Popülasyon: Italian primary care pediatricians

Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None vs: None Outcome: Clinical guideline recommendations for pediatric GI Etki: None None

Popülasyon: Pediatric patients with GI disorders

Controlled Clinical Trial n=24 2 weeks
Protective Effect of Probiotics on Cardiac Damage in Experimental Sepsis Model Induced by Lipopolysaccharide in …
Dose: 10^9 CFU/day for 14 days vs: LPS-only group (no probiotics) Outcome: Cardiac damage markers (CK-MB, cTn-I, cytokines) Etki: None p<0.05 to <0.001

Popülasyon: Male Wistar albino rats with LPS-induced sepsis

Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None vs: None Outcome: None Etki: None None

Popülasyon: Pediatric population

Randomized Controlled Trial Double-blind
A Multi-Hospital Comparative Study on the Efficacy of Probiotics Versus Placebo in Preventing Antibiotic-Associated Diarrhea …
Dose: Probiotics (multi-strain) vs: Placebo Outcome: Antibiotic-associated diarrhea incidence Etki: None None

Popülasyon: Adult patients receiving antibiotics

Review
Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.
Dose: S. boulardii CNCM I-745 vs: Placebo or standard care Outcome: AAD prevention and pediatric gastroenteritis Etki: None None

Popülasyon: AAD and gastroenteritis patients (review)

Key Statistics

20

Çalışmalar

4000

Katılımcılar

Positive

A

Derece

Referenced Papers

Journal of pediatric … 2016 233 atıf
Digestive diseases (Basel, … 2016 37 atıf
Journal of clinical … 2015 35 atıf
Current opinion in … 2009 82 atıf
Advances in biochemical … 2008 535 atıf
The Journal of … 2007 265 atıf

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

general:
10-20 billion CFU/day
ibssupport:
10 billion CFU/day for 4-8 weeks
aadprevention:
10-20 billion CFU/day (start with antibiotic, continue 7 days after)

Üst sınır: Generally well-tolerated up to 40 billion CFU/day in clinical trials

Araştırmalarda İncelenen Dozajlar

Dozaj Süre Etki N
None -- Mixed 279
None -- Positive --
10^9 CFU/day for 14 days 2 weeks Positive 24
None -- Mixed --
Probiotics (multi-strain) -- Positive --
S. boulardii CNCM I-745 -- Positive --
None -- Positive --
Twice daily -- Neutral 2650

En iyi alım zamanı: On an empty stomach or 30 minutes before meals for optimal survival

Safety & Side Effects

Bildirilen Yan Etkiler

  • Mild gas and bloating during initial use (usually resolves in 1-2 weeks)
  • Rare reports of bacteremia in severely immunocompromised individuals
  • Occasional loose stools during adjustment period
  • Very rare: systemic infection in critically ill patients with central venous catheters

Bilinen Etkileşimler

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (theoretical risk of infection in immunocompromised patients)
  • Antifungals (no known interaction but may affect gut flora balance)

Tolere edilebilir üst alım: Generally well-tolerated up to 40 billion CFU/day in clinical trials

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does Lactobacillus rhamnosus GG help with Antibiotic-Associated Diarrhea (AAD)?
Based on 20 studies with 4,000 participants, there is strong evidence from multiple clinical trials that Lactobacillus rhamnosus GG may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Lactobacillus rhamnosus GG should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus GG?
Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus GG and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 20 peer-reviewed studies with 4,000 total participants. The overall direction of effect is positive.

Related Evidence

Şu durum için diğer içerikler: Antibiotic-Associated Diarrhea (AAD)

Lactobacillus rhamnosus GG diğer sağlık durumları için

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.